CVLLY (CellaVision AB) Payments of Debt: $-0.17 Mil (TTM As of Mar. 2026)


CVLLY CellaVision AB CVLLY
69 GF Score
Price $7.06
GF Value $12.48
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is CellaVision AB Payments of Debt?

CellaVision AB CVLLY +12.06% 69 Payments of Debt is $-0.17 Mil as of Mar. 2026. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review.

CellaVision AB's Payments of Debt for the three months ended in Mar. 2026 was $-0.04 Mil.

CellaVision AB's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.17 Mil.

CellaVision AB Payments of Debt Related Terms

CellaVision AB Payments of Debt Historical Data

* Premium members only.

The historical data trend for CellaVision AB's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellaVision AB Payments of Debt Chart

CellaVision AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.43 -3.08 -3.06 -2.64 -0.17

CellaVision AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.04 -0.04 -0.04 -0.04
CVLLY
69GF Score
CellaVision AB CVLLY
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CellaVision AB Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-0.17 Mil mean?
CellaVision AB (CVLLY) has a Payments of Debt of $-0.17 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on CellaVision AB and its competitors.
Is CellaVision AB's Payments of Debt too high?
CellaVision AB's current Payments of Debt is $-0.17 Mil. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Payments of Debt compare to ABT and SYK?
CellaVision AB's Payments of Debt of $-0.17 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Medical Devices & Instruments company?
A good Payments of Debt depends on the Medical Devices & Instruments industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on CellaVision AB and its competitors. CellaVision AB's current Payments of Debt is $-0.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current Payments of Debt is $-0.17 Mil. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current Payments of Debt is $-0.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellaVision AB (CVLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued. The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48. GuruFocus considers CellaVision AB to be Significantly Undervalued.

Key valuation signals for CVLLY:

  • Payments of Debt: $-0.17 Mil
  • GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
  • GF Score™: 69/100 with 1 warning sign

No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CellaVision AB Business Description

Address Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score

Get the complete analysis for CVLLY

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.06
Price
$12.48
GF Value